Compare Novavax Inc (NVAX) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs SoundHound AI Inc — how do they compare? Novavax Inc trades at $9.84 (market cap $1.62B), while SoundHound AI Inc trades at $6.47 (market cap $2.92B). The key difference: SoundHound AI Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | SOUN | |
|---|---|---|
Market Cap | $1.62B | $2.92B |
Sector | Health | Technology |
52-Week High | $11.19 | $21.40 |
52-Week Low | $6.22 | $5.70 |
Enterprise Value | $1.20B | $2.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
SOUN trades at $6.57, down 2.52% today, with a bearish technical signal from moving averages but bullish oscillators. Revenue grew 45% year-over-year in Q2 2026 to $61.9 million, though net income remains negative. The company completed its LivePerson acquisition in September 2026, projecting combined revenue of $350–400 million next year. Analyst consensus is strong with 75% buy ratings and a $8.50 price target, implying 29% upside.
Outlook hinges on scaling the LivePerson integration and achieving profitability, but high short interest (nearly 40%) and persistent cash burn pose risks. The stock offers growth potential if execution succeeds, yet volatility may persist amid competitive and operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
